2,100 Shares in Elevance Health, Inc. (NYSE:ELV) Acquired by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired a new position in Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 2,100 shares of the company’s stock, valued at approximately $775,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC boosted its stake in shares of Elevance Health by 5.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 6,665 shares of the company’s stock valued at $3,466,000 after buying an additional 337 shares during the period. Eastern Bank acquired a new stake in shares of Elevance Health during the 3rd quarter valued at $31,000. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Elevance Health by 35.2% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 1,437 shares of the company’s stock valued at $748,000 after buying an additional 374 shares during the period. Wallington Asset Management LLC boosted its stake in shares of Elevance Health by 26.5% during the 3rd quarter. Wallington Asset Management LLC now owns 506 shares of the company’s stock valued at $263,000 after buying an additional 106 shares during the period. Finally, International Assets Investment Management LLC boosted its stake in shares of Elevance Health by 85,533.1% during the 3rd quarter. International Assets Investment Management LLC now owns 532,638 shares of the company’s stock valued at $276,972,000 after buying an additional 532,016 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

Shares of ELV opened at $390.73 on Friday. The company has a market capitalization of $90.62 billion, a PE ratio of 15.26, a price-to-earnings-growth ratio of 1.15 and a beta of 0.83. Elevance Health, Inc. has a one year low of $362.21 and a one year high of $567.26. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The company’s fifty day moving average price is $385.18 and its 200 day moving average price is $445.29.

Elevance Health (NYSE:ELV) last announced its earnings results on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. As a group, analysts expect that Elevance Health, Inc. will post 34 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be issued a dividend of $1.71 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 annualized dividend and a dividend yield of 1.75%. Elevance Health’s payout ratio is presently 25.46%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ELV shares. Cantor Fitzgerald reissued an “overweight” rating and set a $485.00 target price on shares of Elevance Health in a research note on Friday, January 24th. Barclays lifted their target price on shares of Elevance Health from $501.00 to $512.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. StockNews.com raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Wells Fargo & Company reduced their price objective on shares of Elevance Health from $483.00 to $478.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Finally, Argus reaffirmed a “hold” rating and issued a $405.40 price objective on shares of Elevance Health in a research note on Wednesday, January 29th. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $517.03.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.